SCHEMBL1027553

SCHEMBL1027553

Cc1cc2c(cc1N)C(=O)CCC2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
NPSR1 Q6W5P4 1/20 0.49
MAOA P21397 7/20 0.44
MAOB P27338 7/20 0.44
PRKCI P41743 1/20 0.44
CYP2A6 P11509 1/20 0.41
BAZ2B Q9UIF8 1/20 0.41
HSD17B10 Q99714 2/20 0.40
HSD17B1 P14061 2/20 0.40
CASP1 P29466 1/20 0.39
CASP7 P55210 1/20 0.39
GRM5 P41594 1/20 0.38
BRD4 O60885 1/20 0.37
TSHR P16473 2/20 0.37
CYP3A4 P08684 1/20 0.37
ATAD2 Q6PL18 1/20 0.35
PGR P06401 1/20 0.35
ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10750496 0.93 MAPK1 (0.49) MAPK1MEN1KMT2ANPSR1MAOA
SCHEMBL1025098 0.89 HSD17B10 (0.50) MAPK1MEN1KMT2ANPSR1HSD17B10
SCHEMBL1275258 0.84 MEN1 (0.55) MAPK1MEN1KMT2ANPSR1MAOA
SCHEMBL21772243 0.81 MEN1 (0.49) MAPK1MEN1KMT2ANPSR1MAOA
SCHEMBL15180109 0.81 HSD17B10 (0.50) MAPK1MEN1KMT2ANPSR1HSD17B10
SCHEMBL10389435 0.80 MEN1 (0.50) MAPK1MEN1KMT2ANPSR1MAOA
SCHEMBL10389430 0.80 MEN1 (0.50) MAPK1MEN1KMT2ANPSR1MAOA
SCHEMBL23782883 0.78 MEN1 (0.49) MAPK1MEN1KMT2ANPSR1MAOA
SCHEMBL21155471 0.78 MEN1 (0.49) MAPK1MEN1KMT2ANPSR1MAOA
SCHEMBL7479520 0.78 MEN1 (0.49) MAPK1MEN1KMT2ANPSR1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8513235-B2 Homocysteine synthase inhibitor MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-08-20 US disclosed
EP-2486925-A1 THERAPEUTIC AGENT FOR CEREBRAL INFARCTION Mitsubishi Tanabe Pharma Corporation (JP) 2012-08-15 EP disclosed
US-20120196824-A1 THERAPEUTIC AGENT FOR CEREBRAL INFARCTION MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-08-02 US disclosed
US-20110034440-A1 HOMOCYSTEINE SYNTHASE INHIBITOR MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-02-10 US disclosed
EP-2275404-A1 HOMOCYSTEINE SYNTHASE INHIBITOR Mitsubishi Tanabe Pharma Corporation (JP) 2011-01-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120196824-A1 THERAPEUTIC AGENT FOR CEREBRAL INFARCTION FABP7, TIMP3, MMP11 MAPK1 977/4885MEN1 2301/4885KMT2A 2852/4885
US-20110034440-A1 HOMOCYSTEINE SYNTHASE INHIBITOR BHMT, CBS, BHMT2 MAPK1 1248/4885MEN1 514/4885KMT2A 1006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.